Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys

This publication has 59 references indexed in Scilit:

• Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants
  New England Journal of Medicine, 2008
• Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
  New England Journal of Medicine, 2008
• Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of aPlasmodium falciparumProtein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1
  Infection and Immunity, 2008
• Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research
  Vaccine, 2008
• Preclinical Evaluation of the Safety and Immunogenicity of a Vaccine Consisting ofPlasmodium falciparumLiver-Stage Antigen 1 with Adjuvant AS01B Administered Alone or Concurrently with the RTS,S/AS01B Vaccine in Rhesus Primates
  Infection and Immunity, 2008
• Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity toPlasmodium falciparumCS Compared to That with Either Malaria Vaccine Alone
  Infection and Immunity, 2007
• Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial
  The Lancet, 2005
• Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial
  The Lancet, 2004
• Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
  The Lancet, 2001
• Immunization of man against sporozite-induced falciparum malaria
  The Lancet Healthy Longevity, 1973